{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:52:39Z","timestamp":1781934759016,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BridgeBio Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03425-y","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:28Z","timestamp":1764311368000},"page":"356-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Qualitative Research in Children and Parents of Children with Achondroplasia to Evaluate the Content Validity of Multiple Clinical Outcome Assessments"],"prefix":"10.1007","volume":"43","author":[{"given":"Julie E.","family":"Hoover-Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Savarirayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana Noval","family":"Iruretagoyena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Grumet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary H.","family":"Colwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rogoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Muslimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D.","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"4","key":"3425_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","volume":"246","author":"DM Ornitz","year":"2017","unstructured":"Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Dev Dyn. 2017;246(4):291\u2013309.","journal-title":"Dev Dyn"},{"issue":"1","key":"3425_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14(1):1.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"3425_CR3","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ajmg.a.61787","volume":"182","author":"PK Foreman","year":"2020","unstructured":"Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182(10):2297\u2013316.","journal-title":"Am J Med Genet A"},{"issue":"9582","key":"3425_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","volume":"370","author":"WA Horton","year":"2007","unstructured":"Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370(9582):162\u201372.","journal-title":"Lancet"},{"issue":"2","key":"3425_CR5","first-page":"368","volume":"56","author":"GA Bellus","year":"1995","unstructured":"Bellus GA, Hefferon TW, Ortiz de Luna RI, et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet. 1995;56(2):368\u201373.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"3425_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13023-022-02333-6","volume":"17","author":"NVJ Aldhouse","year":"2022","unstructured":"Aldhouse NVJ, Kitchen H, Johnson C, et al. Key measurement concepts and appropriate clinical outcome assessments in pediatric achondroplasia clinical trials. Orphanet J Rare Dis. 2022;17(1):182.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3425_CR7","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1007\/s12325-023-02549-3","volume":"40","author":"MC Murton","year":"2023","unstructured":"Murton MC, Drane ELA, Goff-Leggett DM, et al. Burden and treatment of achondroplasia: a systematic literature review. Adv Ther. 2023;40(9):3639\u201380.","journal-title":"Adv Ther"},{"issue":"2","key":"3425_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ajmg.a.62534","volume":"188","author":"KM Pfeiffer","year":"2022","unstructured":"Pfeiffer KM, Brod M, Smith A, Viuff D, Ota S, Charlton RW. Functioning and well-being in older children and adolescents with achondroplasia: a qualitative study. Am J Med Genet A. 2022;188(2):454\u201362.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"3425_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13023-019-1171-9","volume":"14","author":"S Witt","year":"2019","unstructured":"Witt S, Kolb B, Bloemeke J, Mohnike K, Bullinger M, Quitmann J. Quality of life of children with achondroplasia and their parents\u2014a German cross-sectional study. Orphanet J Rare Dis. 2019;14(1):194.","journal-title":"Orphanet J Rare Dis"},{"key":"3425_CR10","unstructured":"Mathias SD, Hoover-Fong J, Savarirayan R, et al., editors. Qualitative research in children with achondroplasia and parents of children with achondroplasia: medical challenges and impacts. ENDO. 2022. Atlanta, GA, June 11\u201314."},{"key":"3425_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115872","volume":"146","author":"J Hoover-Fong","year":"2021","unstructured":"Hoover-Fong J, Cheung MS, Fano V, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146:115872.","journal-title":"Bone"},{"issue":"1","key":"3425_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13023-021-01971-6","volume":"16","author":"V Cormier-Daire","year":"2021","unstructured":"Cormier-Daire V, AlSayed M, Ben-Omran T, et al. The first European consensus on principles of management for achondroplasia. Orphanet J Rare Dis. 2021;16(1):333.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3425_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13023-022-02372-z","volume":"17","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan R, Baratela W, Butt T, et al. Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study. Orphanet J Rare Dis. 2022;17(1):224.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3425_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1302\/0301-620X.89B1.18223","volume":"89","author":"ST Lee","year":"2007","unstructured":"Lee ST, Song HR, Mahajan R, Makwana V, Suh SW, Lee SH. Development of genu varum in achondroplasia: relation to fibular overgrowth. J Bone Jt Surg Br. 2007;89(1):57\u201361.","journal-title":"J Bone Jt Surg Br"},{"key":"3425_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115573","author":"W Wrobel","year":"2021","unstructured":"Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: a review. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115573.","journal-title":"Int J Mol Sci"},{"key":"3425_CR16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-1010","author":"J Hoover-Fong","year":"2020","unstructured":"Hoover-Fong J, Scott CI, Jones MC. Health supervision for people with achondroplasia. Pediatrics. 2020. https:\/\/doi.org\/10.1542\/peds.2020-1010.","journal-title":"Pediatrics"},{"issue":"3","key":"3425_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","volume":"18","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan R, Ireland P, Irving M, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18(3):173\u201389.","journal-title":"Nat Rev Endocrinol"},{"key":"3425_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101274","author":"R Savarirayan","year":"2024","unstructured":"Savarirayan R, Irving M, Wilcox WR, et al. Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life. Genet Med. 2024. https:\/\/doi.org\/10.1016\/j.gim.2024.101274.","journal-title":"Genet Med"},{"issue":"4","key":"3425_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1891","volume":"10","author":"R Shediac","year":"2022","unstructured":"Shediac R, Moshkovich O, Gerould H, et al. Experiences of children and adolescents living with achondroplasia and their caregivers. Mol Genet Genom Med. 2022;10(4):e1891.","journal-title":"Mol Genet Genom Med"},{"issue":"1","key":"3425_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11136-020-02594-3","volume":"30","author":"KM Pfeiffer","year":"2021","unstructured":"Pfeiffer KM, Brod M, Smith A, et al. Assessing the impacts of having a child with achondroplasia on parent well-being. Qual Life Res. 2021;30(1):203\u201315.","journal-title":"Qual Life Res"},{"issue":"1","key":"3425_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s13023-021-01978-z","volume":"16","author":"KM Pfeiffer","year":"2021","unstructured":"Pfeiffer KM, Brod M, Smith A, Viuff D, Ota S, Charlton RW. A qualitative study of the impacts of having an infant or young child with achondroplasia on parent well-being. Orphanet J Rare Dis. 2021;16(1):351.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3425_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","volume":"37","author":"JW Varni","year":"1999","unstructured":"Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37(2):126\u201339.","journal-title":"Med Care"},{"key":"3425_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1477-7525-11-76","volume":"11","author":"M Bullinger","year":"2013","unstructured":"Bullinger M, Quitmann J, Power M, et al. Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument. Health Qual Life Outcomes. 2013;11:76.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"3425_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/000992289403300708","volume":"33","author":"ME Msall","year":"1994","unstructured":"Msall ME, DiGaudio K, Rogers BT, et al. The functional independence measure for children (WeeFIM). Conceptual basis and pilot use in children with developmental disabilities. Clin Pediatr (Phila). 1994;33(7):421\u201330.","journal-title":"Clin Pediatr (Phila)"},{"issue":"1","key":"3425_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ajmg.a.61903","volume":"185","author":"KM Pfeiffer","year":"2021","unstructured":"Pfeiffer KM, Brod M, Smith A, et al. Assessing physical symptoms, daily functioning, and well-being in children with achondroplasia. Am J Med Genet A. 2021;185(1):33\u201345.","journal-title":"Am J Med Genet A"},{"issue":"15","key":"3425_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1080\/09638288.2018.1447028","volume":"41","author":"J Bloemeke","year":"2019","unstructured":"Bloemeke J, Sommer R, Witt S, et al. Piloting and psychometric properties of a patient-reported outcome instrument for young people with achondroplasia based on the International Classification of Functioning Disability and Health: the Achondroplasia Personal Life Experience Scale (APLES). Disabil Rehabil. 2019;41(15):1815\u201325.","journal-title":"Disabil Rehabil"},{"issue":"9","key":"3425_CR27","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s11136-019-02210-z","volume":"28","author":"J Bloemeke","year":"2019","unstructured":"Bloemeke J, Sommer R, Witt S, et al. Cross-cultural selection and validation of instruments to assess patient-reported outcomes in children and adolescents with achondroplasia. Qual Life Res. 2019;28(9):2553\u201363.","journal-title":"Qual Life Res"},{"key":"3425_CR28","unstructured":"Mathias SD, Hoover-Fong J, Savarirayan R, et al., editors. A background review of several generic patient-reported outcome and clinician-reported outcome measures: selecting measures for further evaluation in a qualitative study in achondroplasia. In: 60th Annual European Society for Paediatric Endocrinology (ESPE) meeting. 2022. Rome, Italy, Sept 15\u201317."},{"key":"3425_CR29","unstructured":"Mathias SD, Hoover-Fong J, Savarirayan R, et al., editors. Mapping of important concepts during qualitative interviews of children with achondroplasia (ACH) and parents of children with ACH to select patient-reported outcome measures and a clinician-reported outcome measure. In: ASBMR annual meeting. 2022. Austin, Texas, Sep 9\u201311."},{"key":"3425_CR30","unstructured":"Mathias SD, Hoover-Fong J, Savarirayan R, et al., editors. A comprehensive assessment of patient-reported outcome measures in children and parents of children with achondroplasia: results from a qualitative research and mapping exercise. In: 60th Annual European Society for Paediatric Endocrinology (ESPE) meeting. 2022. Rome, Italy, Sept 15\u201317."},{"key":"3425_CR31","unstructured":"Mathias SD, Hoover-Fong J, Savarirayan R, et al., editors. Qualitative research in children and parents of children with achondroplasia: Medical challenges and impacts and their assessment using patient-reported outcome measures. In: 15th International Skeletal Dysplasia Society (ISDS) meeting. 2022. Santiago, Chile, Aug 24\u201327."},{"issue":"10","key":"3425_CR32","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1469-8749.2011.04050.x","volume":"53","author":"PJ Ireland","year":"2011","unstructured":"Ireland PJ, McGill J, Zankl A, et al. Functional performance in young Australian children with achondroplasia. Dev Med Child Neurol. 2011;53(10):944\u201350.","journal-title":"Dev Med Child Neurol"},{"key":"3425_CR33","doi-asserted-by":"crossref","unstructured":"WeeFIM II\u00ae. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. New York: Springer; 2011. p. 2694.","DOI":"10.1007\/978-0-387-79948-3_4889"},{"key":"3425_CR34","volume-title":"The WeeFIM II(R) clinical guide, version 6.4","author":"Uniform Data System for Medical Rehabilitation","year":"2016","unstructured":"Uniform Data System for Medical Rehabilitation. The WeeFIM II(R) clinical guide, version 6.4. Buffalo: UDSMR; 2016."},{"issue":"2","key":"3425_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BPO.0b013e3181652185","volume":"28","author":"DD Allen","year":"2008","unstructured":"Allen DD, Gorton GE, Oeffinger DJ, Tylkowski C, Tucker CA, Haley SM. Analysis of the pediatric outcomes data collection instrument in ambulatory children with cerebral palsy using confirmatory factor analysis and item response theory methods. J Pediatr Orthop. 2008;28(2):192\u20138.","journal-title":"J Pediatr Orthop"},{"issue":"8","key":"3425_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s11136-007-9240-2","volume":"16","author":"U Ravens-Sieberer","year":"2007","unstructured":"Ravens-Sieberer U, Auquier P, Erhart M, et al. The KIDSCREEN-27 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries. Qual Life Res. 2007;16(8):1347\u201356.","journal-title":"Qual Life Res"},{"issue":"6","key":"3425_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","volume":"19","author":"N Wille","year":"2010","unstructured":"Wille N, Badia X, Bonsel G, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875\u201386.","journal-title":"Qual Life Res"},{"issue":"6","key":"3425_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.anpedi.2024.09.005","volume":"101","author":"AC Barreda-Bonis","year":"2024","unstructured":"Barreda-Bonis AC, de Bergua Domingo JM, Gal\u00e1n-G\u00f3mez E, Guill\u00e9n-Navarro E, Leiva-Gea I, Ria\u00f1o-Gal\u00e1n I. Expert consensus for the management of patients with achondroplasia in treatment with vosoritide. An Pediatr (Engl Ed). 2024;101(6):401\u201310.","journal-title":"An Pediatr (Engl Ed)"},{"key":"3425_CR39","unstructured":"Irving M, AlSayed M, Baujat G, et al., editors. European Achondroplasia Forum: are current outcome measures for achondroplasia still fit for purpose in the era of medical management? In: Annual European Society for Paediatric Endrocrinology (ESPE) meeting. 2024. Liverpool, UK, Nov 16\u201318."},{"key":"3425_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/children11070789","author":"L Tofts","year":"2024","unstructured":"Tofts L, Ireland P, Tate T, et al. Consensus guidelines for the use of vosoritide in children with achondroplasia in Australia. Children (Basel). 2024. https:\/\/doi.org\/10.3390\/children11070789.","journal-title":"Children (Basel)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03425-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:32:15Z","timestamp":1769765535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03425-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3425"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03425-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised due to update in Tale 2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julie E. Hoover-Fong has received grants or contracts from clinical trials from BioMarin, BridgeBio Pharma and Pfizer, has received consulting fees from BioMarin, BridgeBio Pharma, NovoNordisk and Innoskel, has received honoraria from Medscape and BioMarin, and has participated on advisory boards with MCDS-Therapy Clinical Trial (unpaid), BioMarin and Bridgebio Pharma. Ravi Savarirayan has received consulting fees and grants from BioMarin, has participated on advisory boards with Ascendis and BioMarin, and has received consulting fees from BridgeBio Pharma. Anne Grumet, Daniela Rogoff, and Elena Muslimova,are employees and shareholders of BridgeBio Pharma. Susan D. Mathias is an employee and Hilary H. Colwell is a consultant to Health Outcomes Solutions, which received funding from BridgeBio Pharma for undertaking this research. In\u00eas Alves, Chandler Crews, Amer Haider, and Susana Noval Iruretagoyena report no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Human participants\u2019 research approval for the study was provided by an independent scientific review committee, WCG IRB (20214002). All participants that contributed data provided informed consent as part of the research associated with data collection. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}